NORGESIC by Bausch + Lomb is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. First approved in 1964.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
NORGESIC is an oral fixed-dose combination tablet containing orphenadrine citrate, aspirin, and caffeine approved in 1964. It is a centrally acting muscle relaxant that blocks facilitatory functions of the reticular formation in the brain stem, used for musculoskeletal pain and spasticity. The exact therapeutic mechanism remains incompletely understood, though analgesic and anticholinergic properties contribute to its effect.
As a 60-year-old product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely in defensive or maintenance mode with focused resource allocation.
CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NORGESIC presents limited career growth opportunities given its LOE-approaching status and zero linked job postings. Roles available typically focus on lifecycle management, generic transition strategy, and profit protection rather than market expansion or innovation.
Worked on NORGESIC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.